Skip Navigation

Hematology and Medical Oncology

In the departmental listings, the following notations signify particular faculty appointments:

* Secondary appointment
+ Part time
^ Faculty member with secondary appointment outside the School of Medicine
# Faculty member with primary appointment outside the School of Medicine

Fadlo Khuri, Professor of Medicine, Roberto C. Goizueta Chair for Cancer Research, Chair of the Department

Professor Emeritus

James R. Eckman, Laurence A. Harker


Jonathan Beitler*, Lawrence H. Boise, Otis W. Brawley, Georgia Z Chen, Paul William Doetsch*, Jin-Tang Dong, Carl D'Orsi*, John W. Eley, Haian Fu*, Jacques Galipeau, Anand Jillella, Hanna J. Khoury,  Fadlo R. Khuri, Omer Kucuk, Amelia A Langston, David Lawson, Dennis C. Liotta*, Sagar Lonial, Andrew H. Miller*,  Suresh Ramalingam, Ruth M. O'Regan, Rebecca D. Pentz, Rein Saral, Dong M. Shin, Sidney F Stein, Shi-Yong Sun, Edmund K. Waller,  Elliott F Winton

Associate Professors

George Garland Birdsong II*, Amy Y. Chen, Jing Chen, Bassel F. El Rayes, Christopher R. Flowers, Theresa W. Gillespie*, Ronald Donald Harvey, Leonard T. Heffner Jr., Ira Horowitz*, Jonathan L Kaufman, John S. W, Kauh, Kevin (Hyun Sik) Kim*, Mary Jo Lechowicz, Adam I. Marcus, Shuming Nie*, Taokfeek K. Owonikoko, William L Read, Nabil F Saba, Mamoru Shoji, Shan Ping Yu, Wei Zhou

Assistant Professors

Jack Arbiser*, A. R. M. Ruhul Amin, Ana Antun, Martha Arellano, Leon Bernal-Mizrachi, Chandar Bhimani, Johann C. Brandes, Bradley Carthon, Samuel N. Chan, Zhengja Chen*, Nelson Chen*, Jonathon Cohen, Laronna Colbert, Ian Copland, Ian R. Crocker*, Xueyan Dong, Alexander Duncan*, Manila Gaddh, Wayne B. Harris, Mohammad S. Hossain, Cynthia R. Giver, Natalyn Hawk, Sumin Kang, Christine L. Kempton*, Jerome C. Landry*, Robert H. Lyles*, W. David Martin, Morgan L. McLemore, Abid Mohiuddin, David Monson*, Melvin R Moore, Carlos C. Moreno*, Ajay K. Nooka, Gregg Orloff, Suchita Pakkala,  Xiang Hong Peng, John A. Petros*, Reddy, Maria J. Ribeiro, Ioannis Sechopoulos*,  Mala Shanmugam, Mark J. Shumate, George Sorescu, Trent Spencer*, Toncred Styblo*, Geetha Vallabhaneni, Alfredo D. Voloschin, Jens P Wrammert, Chunzhi Xia, Lily Yang*, Amelia Zelnak


Jiusheng Deng, Jun Fan, Purnachandra Ganji, Melissa Gilbert-Ross, Latonia Taliaferro Smith, Shijun Zhu

Adjunct Professor

Masayoshi Yamaguchi, Ali Taher

Adjunct Assistant Professor

Joan Elizabeth Cain, Allan Freedman, William Jonas, Mary Jo Lund, Muqsita Nashat, Frederick M. Schnell, Trevor McKibbon


Walter J. Curran*, Director, Winship Cancer Institute

The newest department established by the School of Medicine highlights the importance of Emory's Winship Cancer Institute as a comprehensive cancer center. The department includes faculty who are leaders in research and clinical treatment of many forms of cancer, including lung and aerodigestive cancers. There is also a fellowship program in the Department. As part of the Winship Cancer Institute, The Department of Hematology and Medical Oncology supports multidisciplinary efforts at Emory University to improve the care of patients with cancer and contribute new knowledge to solving the problem of cancer and contains the sections of hematology, bone marrow transplant, and medical oncology.

The Winship Cancer Institute emphasizes a multidisciplinary approach to cancer education, control, epidemiology, therapy, and basic research in tumor biology. The center undertakes clinical and basic research in biochemistry, molecular biology, immunology, cell biology, and chemotherapy. It maintains shared facilities of specialized technologies and provides a focus for interaction of Emory scientists involved in cancer research. The institute offers opportunities for students to participate in elective studies during summer months and provides educational programs for both students and faculty.

Elective Opportunities

There are electives that include understanding key concepts in the subspecialty of hematology and oncology, and recent advances, learning how to evaluate patients for hematologic disorders both malignant and benign, following patients with a diagnosis of cancer, integrate pathology, genetics and molecular biology in the management of these patients, opportunities to generate hypotheses from patients seen that would be appropriate for testing in a clinical trial, and a review of the pivotal basic scientific discoveries in this field in the last decade.